2019年全球药品销售额TOP100,肿瘤与自身免疫蛋糕惊人

2020-04-14 医药魔方 医药魔方

根据各家生物制药公司2019财报披露的产品销售数据,2019年全球销售额超过10亿美元的重磅炸弹药品共有140个。其中,TOP100药品的上榜门槛是14.69亿美元(约合人民币102.83亿元),合计

根据各家生物制药公司2019财报披露的产品销售数据,2019年全球销售额超过10亿美元的重磅炸弹药品共有140个。其中,TOP100药品的上榜门槛是14.69亿美元(约合人民币102.83亿元),合计销售收入3402.87亿美元。

梅斯医学小编发现,阿达木仍然排在首位,超过191亿美元,多年来阿达木一直象神一样居于榜首。不过,在中国国内市场始终不理想,这也反映中国与国外的市场环境的重大差异。阿哌沙班超过120亿大品种,而利伐沙班接近70亿。接下来是大名鼎鼎的K药,超过110亿,预计2020年会超过150亿大关,未来有望突破200亿的可能。O药略低,也有80亿美元。贝伐单抗虽然上市N年,仿制药也已上市,目前仍然有71亿美元,得益于罗氏不断深入研究贝伐,将贝伐的适应症不段拓展。从与化疗联合,到与靶向联合,到如今与肿瘤免疫联合,其生命力不断得到延伸,成为经典。

整体而言,肿瘤,自身免疫是最大头,其次是核心慢病,如卒中,糖尿病等。在未来,很多企业的研发重心仍然放在肿瘤,自身免疫两块核心蛋糕身上。

从品类来看,梅斯医学小编认为,因为肿瘤与自身免疫的治疗绝大部分是单抗药物,未来单抗药物的后劲十足,有望接近,甚至超过小分子药物(小分子药物的数量众多,而且也包括了抗肿瘤的小分子靶向药物)。同时,双特异性抗体、纳米抗体、ADC类抗体等不断问世,有望扩大单抗家族版图,提升单抗类药物的市场份额。

表1. 2019年全球药品销售额TOP100(亿美元)

从药物类型上看,TOP100药品中小分子药物共54个,销售收入占比46%。单抗/重组蛋白类大分子药物共40个,销售收入占比49%。如果把范围缩小到TOP10,销售收入总计908.01亿美元,其中小分子药物共4个,销售收入占比39%,单抗/重组蛋白类大分子药物共6个,销售收入占比达到了61%。

表2. 2019年TOP100药品类型分布(数量、销售收入)

 

从疾病领域来看,TOP100药品中肿瘤、免疫、感染病、内分泌、心血管、神经疾病是市场规模最大的6个领域,均超过了200亿美元。

表3. 2019年TOP100药品疾病领域分布(数量、销售收入)

具体药品而言, Biktarvy(艾滋病,吉利德)、Dupixent(特应性皮炎,赛诺菲)、Shingrix(带状疱疹疫苗,GSK)、Imfinzi(肺癌/膀胱癌,阿斯利康)均是以120%以上的同比增幅首次进入全球TOP100畅销药榜单。

以上内容主要来自医药魔方,略有增补

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1687373, encodeId=6260168e37345, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Sat Dec 12 14:03:19 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649867, encodeId=ef26164986ede, content=<a href='/topic/show?id=f1e41e642cd' target=_blank style='color:#2F92EE;'>#TOP10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17642, encryptionId=f1e41e642cd, topicName=TOP10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb7b23929551, createdName=respect, createdTime=Sat Sep 12 23:03:19 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950643, encodeId=c8be1950643ab, content=<a href='/topic/show?id=d0988e506bd' target=_blank style='color:#2F92EE;'>#药品销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87506, encryptionId=d0988e506bd, topicName=药品销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed May 20 17:03:19 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377278, encodeId=502b13e7278aa, content=<a href='/topic/show?id=ff9f8e5076f' target=_blank style='color:#2F92EE;'>#药品销售额#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87507, encryptionId=ff9f8e5076f, topicName=药品销售额)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Apr 16 04:03:19 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379924, encodeId=d01c13e992478, content=<a href='/topic/show?id=979f966e5f7' target=_blank style='color:#2F92EE;'>#销售额#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96675, encryptionId=979f966e5f7, topicName=销售额)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Thu Apr 16 04:03:19 CST 2020, time=2020-04-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1687373, encodeId=6260168e37345, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Sat Dec 12 14:03:19 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649867, encodeId=ef26164986ede, content=<a href='/topic/show?id=f1e41e642cd' target=_blank style='color:#2F92EE;'>#TOP10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17642, encryptionId=f1e41e642cd, topicName=TOP10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb7b23929551, createdName=respect, createdTime=Sat Sep 12 23:03:19 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950643, encodeId=c8be1950643ab, content=<a href='/topic/show?id=d0988e506bd' target=_blank style='color:#2F92EE;'>#药品销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87506, encryptionId=d0988e506bd, topicName=药品销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed May 20 17:03:19 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377278, encodeId=502b13e7278aa, content=<a href='/topic/show?id=ff9f8e5076f' target=_blank style='color:#2F92EE;'>#药品销售额#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87507, encryptionId=ff9f8e5076f, topicName=药品销售额)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Apr 16 04:03:19 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379924, encodeId=d01c13e992478, content=<a href='/topic/show?id=979f966e5f7' target=_blank style='color:#2F92EE;'>#销售额#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96675, encryptionId=979f966e5f7, topicName=销售额)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Thu Apr 16 04:03:19 CST 2020, time=2020-04-16, status=1, ipAttribution=)]
    2020-09-12 respect
  3. [GetPortalCommentsPageByObjectIdResponse(id=1687373, encodeId=6260168e37345, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Sat Dec 12 14:03:19 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649867, encodeId=ef26164986ede, content=<a href='/topic/show?id=f1e41e642cd' target=_blank style='color:#2F92EE;'>#TOP10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17642, encryptionId=f1e41e642cd, topicName=TOP10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb7b23929551, createdName=respect, createdTime=Sat Sep 12 23:03:19 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950643, encodeId=c8be1950643ab, content=<a href='/topic/show?id=d0988e506bd' target=_blank style='color:#2F92EE;'>#药品销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87506, encryptionId=d0988e506bd, topicName=药品销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed May 20 17:03:19 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377278, encodeId=502b13e7278aa, content=<a href='/topic/show?id=ff9f8e5076f' target=_blank style='color:#2F92EE;'>#药品销售额#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87507, encryptionId=ff9f8e5076f, topicName=药品销售额)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Apr 16 04:03:19 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379924, encodeId=d01c13e992478, content=<a href='/topic/show?id=979f966e5f7' target=_blank style='color:#2F92EE;'>#销售额#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96675, encryptionId=979f966e5f7, topicName=销售额)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Thu Apr 16 04:03:19 CST 2020, time=2020-04-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1687373, encodeId=6260168e37345, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Sat Dec 12 14:03:19 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649867, encodeId=ef26164986ede, content=<a href='/topic/show?id=f1e41e642cd' target=_blank style='color:#2F92EE;'>#TOP10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17642, encryptionId=f1e41e642cd, topicName=TOP10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb7b23929551, createdName=respect, createdTime=Sat Sep 12 23:03:19 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950643, encodeId=c8be1950643ab, content=<a href='/topic/show?id=d0988e506bd' target=_blank style='color:#2F92EE;'>#药品销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87506, encryptionId=d0988e506bd, topicName=药品销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed May 20 17:03:19 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377278, encodeId=502b13e7278aa, content=<a href='/topic/show?id=ff9f8e5076f' target=_blank style='color:#2F92EE;'>#药品销售额#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87507, encryptionId=ff9f8e5076f, topicName=药品销售额)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Apr 16 04:03:19 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379924, encodeId=d01c13e992478, content=<a href='/topic/show?id=979f966e5f7' target=_blank style='color:#2F92EE;'>#销售额#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96675, encryptionId=979f966e5f7, topicName=销售额)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Thu Apr 16 04:03:19 CST 2020, time=2020-04-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1687373, encodeId=6260168e37345, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Sat Dec 12 14:03:19 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649867, encodeId=ef26164986ede, content=<a href='/topic/show?id=f1e41e642cd' target=_blank style='color:#2F92EE;'>#TOP10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17642, encryptionId=f1e41e642cd, topicName=TOP10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb7b23929551, createdName=respect, createdTime=Sat Sep 12 23:03:19 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950643, encodeId=c8be1950643ab, content=<a href='/topic/show?id=d0988e506bd' target=_blank style='color:#2F92EE;'>#药品销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87506, encryptionId=d0988e506bd, topicName=药品销售)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Wed May 20 17:03:19 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377278, encodeId=502b13e7278aa, content=<a href='/topic/show?id=ff9f8e5076f' target=_blank style='color:#2F92EE;'>#药品销售额#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87507, encryptionId=ff9f8e5076f, topicName=药品销售额)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Apr 16 04:03:19 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379924, encodeId=d01c13e992478, content=<a href='/topic/show?id=979f966e5f7' target=_blank style='color:#2F92EE;'>#销售额#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96675, encryptionId=979f966e5f7, topicName=销售额)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Thu Apr 16 04:03:19 CST 2020, time=2020-04-16, status=1, ipAttribution=)]
    2020-04-16 zxl729

相关资讯

盘点:2020年度J Clin Oncol杂志回顾汇总(三)

J Clin Oncol:2020年ASCO临床肿瘤学年度进展报告

PNAS:肿瘤发生过程中的肠道宿主-微生物平衡调控

在所有动物体内,肠道上皮形成了一道严密的环境屏障。肠上皮调节营养物质的吸收、免疫反应,并防止全身感染。

J Immunother Cancer:营养与健康所等揭示中药复方苦参注射液增敏索拉菲尼治疗肝癌新机制

该研究表明,中药复方苦参注射液通过TNFR1解除肿瘤免疫微环境中的肿瘤相关巨噬细胞(TAMs)引起的免疫抑制,从而增敏低剂量索拉菲尼的肝癌治疗效果,为肝癌的临床治疗提供了新策略。

Molecular therapy: methods&clinical development:癌症科学家的目标,利用蛋白质的力量来阻止肿瘤的生长

导言:癌症是威胁人类健康的重大疾病,因此对于肿瘤与机体之间相互作用的研究及新型抗癌药物的开发具有极大的学术和社会价值。肿瘤的发生发展与肿瘤微环境密切相关,细胞因子是肿瘤微环境的重要组成部分,因此研究不

JAMA Oncol:谢丛华教授发现肿瘤患者感染新冠病毒的风险是普通人群的2.31倍

3月25日,国际医学期刊《JAMA Oncology》在线发表了由武汉大学中南医院肿瘤放化疗科谢丛华教授及团队针对肿瘤患者新冠肺炎感染风险的一篇文章

Cell Death Dis:核糖体成熟因子SBDS双重调控p53

SBDS基因,因与Shwachman-Bodian Diamond综合征(SBDS)高度相关而得名。该综合征的主要特征为胰腺功能障碍、血液循环系统衰竭、骨骼畸形及神经系统相关表型。SBDS基因能够参与